Dr. Reddy's Laboratories Limited (NSE:DRREDDY)

Market Cap	1.07T +7.1%
Revenue (ttm)	345.83B +11.1%
Net Income	56.59B +5.4%
EPS	67.93 +5.6%
Shares Out	n/a
PE Ratio	18.85
Forward PE	22.62
Dividend	8.00 (0.63%)
Ex-Dividend Date	Jul 10, 2025

Volume	302,730
Average Volume	1,605,456
Open	1,290.00
Previous Close	1,280.30
Day's Range	1,285.80 - 1,295.70
52-Week Range	1,020.00 - 1,379.70
Beta	0.29
RSI	60.35
Earnings Date	Jan 21, 2026

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1984
• Employees: 27,811
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: DRREDDY

Financial Performance

In fiscal year 2025, Dr. Reddy's Laboratories's revenue was 325.54 billion, an increase of 16.61% compared to the previous year's 279.16 billion. Earnings were 56.54 billion, an increase of 1.54%.